Fibroblast Growth Factor (fgf) Or Derivative Patents (Class 514/9.1)
  • Publication number: 20110039774
    Abstract: The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.
    Type: Application
    Filed: August 13, 2010
    Publication date: February 17, 2011
    Applicant: EU SOL BIOTECH CO., LTD.
    Inventors: HENRICH CHENG, MING-JEI LO, YEE-CHIANG LIU
  • Publication number: 20110034383
    Abstract: Fragments of CXCL12 Gamma A chemokine having improved chemotaxis activity in vivo defined by an unprecedented capacity to associate and immobilise on extracellular glycans.
    Type: Application
    Filed: October 15, 2008
    Publication date: February 10, 2011
    Applicant: INSTITUT PASTEUR
    Inventors: Fernando Arenzana, Hugues Lortat-Jacob, Francoise Baleux
  • Publication number: 20110034373
    Abstract: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.
    Type: Application
    Filed: July 30, 2008
    Publication date: February 10, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Tamer Coskun, Wolfgang Glaesner
  • Publication number: 20110033503
    Abstract: Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed.
    Type: Application
    Filed: April 23, 2008
    Publication date: February 10, 2011
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Stanley Stein, Anupa R. Menjoge, Simi Gunaseelan, Siva Naga Sree priay Anumolu, Raghavandra Navath
  • Publication number: 20110033543
    Abstract: A method for targeted delivery of therapeutic compounds from hydrogels is presented. The method involves administering to a cell a hydrogel in which a therapeutic compound is noncovalently bound to heparin. The hydrogel may contain covalent and non-covalent crosslinks.
    Type: Application
    Filed: June 14, 2010
    Publication date: February 10, 2011
    Inventors: Kristi L. Kiick, Nori Yamaguchi
  • Patent number: 7884072
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: February 8, 2011
    Assignee: Stem Cell Therapeutics Inc.
    Inventors: Tetsuro Shingo, Samuel Weiss
  • Publication number: 20110027221
    Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
    Type: Application
    Filed: September 24, 2008
    Publication date: February 3, 2011
    Applicants: TIANJIN SINOBIOTECH LTD., FORTUNEROCK, INC. USA
    Inventors: Yan Fu, Zailin Yu
  • Publication number: 20110027257
    Abstract: The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGT-?, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating the platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and/or the detergent by oil extraction and/or chromatographic means.
    Type: Application
    Filed: January 7, 2009
    Publication date: February 3, 2011
    Applicant: GWO REI BIOMEDICAL TECHNOLOGY CORPORATION
    Inventors: Thierry Burnouf, Cheng-Yao Su
  • Publication number: 20110020271
    Abstract: The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.
    Type: Application
    Filed: May 20, 2010
    Publication date: January 27, 2011
    Applicant: Humacyte, Inc.
    Inventors: Laura E. Niklason, Yuling Li, Heather Prichard, Shannon Dahl, Juliana Blum
  • Patent number: 7875591
    Abstract: A device comprising a scaffold coated with a protein having at least 83% identity to the amino acid sequence of the core protein of domain I of a mammalian perlecan, wherein at least one glycosaminoglycan is attached to the protein is described. The device may be used in vitro or in vivo to induce replication and/or differentiation of connective tissue cells and to repair tissue.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: January 25, 2011
    Assignee: University of Delaware
    Inventors: Daniel D. Carson, Mary C. Farach-Carson, Margaret French, Ronald Gomes
  • Publication number: 20110008281
    Abstract: The present invention provides methods, compositions, and systems for treating a subject at risk for, with, or suspected of having, myocardial ischemia using hepatocyte secretory factors (e.g., AGP2, BMPER, FGF21, NRG4, and/or TFF3) or using factors that promote liver cell migration to ischemic myocardial tissue (e.g., IL-6 and/or MMP-2).
    Type: Application
    Filed: July 9, 2010
    Publication date: January 13, 2011
    Applicant: NORTHWESTERN UNIVERSITY
    Inventor: Shu Q. Liu
  • Publication number: 20110002880
    Abstract: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable ?-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.
    Type: Application
    Filed: December 4, 2008
    Publication date: January 6, 2011
    Applicant: 3-D MATRIX, LTD.
    Inventors: Kentaro Takamura, Jiro Takei
  • Patent number: 7858577
    Abstract: The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: December 28, 2010
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Alberto Mantovani, Barbara Bottazzi, Marco Presta, Marco Rusnati
  • Publication number: 20100322908
    Abstract: The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive.
    Type: Application
    Filed: March 2, 2009
    Publication date: December 23, 2010
    Inventors: Hanne Everland, Peter Samuelsen, Jakob Vange, Christian Clausen, Monica Ramos Gallego
  • Publication number: 20100323962
    Abstract: The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8.
    Type: Application
    Filed: April 21, 2010
    Publication date: December 23, 2010
    Inventor: Abburi Ramaiah
  • Publication number: 20100323954
    Abstract: The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 23, 2010
    Applicant: AMGEN INC.
    Inventors: Yang LI, Xinle Wu, Zhulun Wang
  • Publication number: 20100322872
    Abstract: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, lactoferrin, lactoferrin peptides, lysozyme and immunoglobulins and at least one growth factor.
    Type: Application
    Filed: August 3, 2010
    Publication date: December 23, 2010
    Inventor: Jean-Paul Perraudin
  • Publication number: 20100303884
    Abstract: Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, KGF, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required.
    Type: Application
    Filed: June 3, 2010
    Publication date: December 2, 2010
    Inventors: Zee Upton, Christopher Luke Towne
  • Publication number: 20100303886
    Abstract: Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).
    Type: Application
    Filed: August 12, 2010
    Publication date: December 2, 2010
    Inventor: Abram D. Janis
  • Publication number: 20100305500
    Abstract: Embodiments of the invention relate to hyaluronidase as an adjuvant to increase the injection volume and dispersion of large diameter synthetic membrane vesicles containing one or more therapeutic agents. In particular, embodiments of the invention relate to compositions comprising hyaluronidase and large diameter synthetic membrane vesicles containing a therapeutic agent, and methods of administration of the same. Methods of making large diameter synthetic membrane vesicles containing an active pharmaceutical ingredient and their use in combination with hyaluronidase as medicaments are provided.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 2, 2010
    Applicant: PACIRA PHARMACEUTICALS, INC.
    Inventors: William LAMBERT, Jason REXROAD
  • Publication number: 20100303793
    Abstract: An agonist of the non-proteolytically activated thrombin receptor and an angiogenic growth factor can be used in combination in methods of therapy to stimulate cardiac revascularization, to stimulate vascular endothelial cell proliferation, to stimulate vascular endothelial cell migration and to promote repair of cardiac tissue.
    Type: Application
    Filed: April 10, 2008
    Publication date: December 2, 2010
    Inventors: Barbara Olszewska-Pazdrak, Darrell H. Carney
  • Publication number: 20100297238
    Abstract: A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin.
    Type: Application
    Filed: April 27, 2010
    Publication date: November 25, 2010
    Inventors: Kristi L. Kiick, Nori Yamaguchi, John Rabolt, Cheryl Casper
  • Publication number: 20100298220
    Abstract: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided.
    Type: Application
    Filed: May 19, 2010
    Publication date: November 25, 2010
    Applicant: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: MICHAEL BLABER, JIHUN LEE
  • Publication number: 20100297066
    Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.
    Type: Application
    Filed: May 14, 2008
    Publication date: November 25, 2010
    Inventors: Joshua B. Stopek, Brian Cuevas
  • Publication number: 20100297074
    Abstract: The present disclosure relates, according to some embodiments, to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the disclosure may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.
    Type: Application
    Filed: April 9, 2010
    Publication date: November 25, 2010
    Inventors: Richard Hans Gomer, Darrell Pilling
  • Publication number: 20100291069
    Abstract: Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy.
    Type: Application
    Filed: May 13, 2010
    Publication date: November 18, 2010
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: E. Albert REECE, Zhiyong ZHAO, Peixin YANG
  • Publication number: 20100291212
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Application
    Filed: May 20, 2010
    Publication date: November 18, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Publication number: 20100286028
    Abstract: The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
    Type: Application
    Filed: September 9, 2008
    Publication date: November 11, 2010
    Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
  • Publication number: 20100286793
    Abstract: Described are medical devices configured for use in cosmetic surgery. The medical devices include an elongate body member having a proximal end, a distal end, and a plurality of gaps defined therebetween. At least a portion of the body member is associated with one or more layers of a collagenous extracellular matrix (ECM) material. The elongate member can include one or more tissue engaging members. In preferred embodiments, the collagenous extracellular matrix material includes one or more native or non-native bioactive components.
    Type: Application
    Filed: May 6, 2010
    Publication date: November 11, 2010
    Inventors: Nathan Newman, Umesh H. Patel
  • Publication number: 20100285131
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 11, 2010
    Applicant: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Publication number: 20100286042
    Abstract: There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 11, 2010
    Applicant: National Institute of advanced Industrial Science and Technology
    Inventors: Toru Imamura, Kaori Motomura, Akiko Kuramochi, Yoshiro Hanyu, Masashi Suzuki, Masahiro Asada, Akiko Hagiwara, Fumiaki Nakayama, Makoto Akashi
  • Publication number: 20100274362
    Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the ?8-?9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the ?8-?9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.
    Type: Application
    Filed: January 14, 2010
    Publication date: October 28, 2010
    Inventors: Avner Yayon, Katherine G. Truncale, Hilla Barkay-Olami, Alex B. Callahan, Arthur A. Gertzman, Yen-Chen Huang, Morris L. Jacobs, John C. Munson, Eric J. Semler, Roman Shikhanovich, Baruch Stern, Moon Hae Sunwoo, William W. Tomford, Judith I. Yannariello-Brown
  • Publication number: 20100266654
    Abstract: Described are medical compositions including a collagenous ECM particulate dispersed in a carrier. Such medical compositions can be applied to at least a portion of a surface of a sheet of collagenous ECM material to form a medical product. Medical compositions and products as described herein find particular use in wound repair. Related methods of manufacture and use are also described.
    Type: Application
    Filed: June 28, 2010
    Publication date: October 21, 2010
    Inventors: Jason P. Hodde, Umesh H. Patel
  • Publication number: 20100254901
    Abstract: Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.
    Type: Application
    Filed: July 28, 2006
    Publication date: October 7, 2010
    Inventor: Cassandra L. Smith
  • Publication number: 20100247627
    Abstract: The present invention provides methods and compositions for modulating skin pigmentation.
    Type: Application
    Filed: March 30, 2010
    Publication date: September 30, 2010
    Inventors: Janice Brissette, Lorin Weiner, Rong Han, Rebecca Campen
  • Publication number: 20100247483
    Abstract: The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetic s thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants.
    Type: Application
    Filed: November 21, 2009
    Publication date: September 30, 2010
    Inventor: Loi H. Tran
  • Publication number: 20100239554
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: February 3, 2010
    Publication date: September 23, 2010
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland
  • Publication number: 20100239654
    Abstract: The present invention relates to a pharmaceutical composition for sustained release of a pharmaceutically active compound, the composition comprising a vesicular phospholipid gel. More particularly, the invention relates to a pharmaceutical composition comprising at least one proteinaceous substance as the pharmaceutically active compound in encapsulated form, the at least one proteinaceous substance being a biologically active protein, peptide or polypeptide. Furthermore, the present invention relates to a method for the production of said pharmaceutical composition comprising dual asymmetric centrifugation and to the use of said pharmaceutical composition for immunotherapy and/or for stimulating selective tissue regeneration in the treatment of surgical defects in the course of surgical interventions.
    Type: Application
    Filed: January 22, 2010
    Publication date: September 23, 2010
    Inventor: Gerhard Winter
  • Patent number: 7125862
    Abstract: A porphyrin metal complex that can form a stable oxygen complex and acts effectively as an oxygen infusion, which comprises: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general wherein R1 is an alicyclic hydrocarbon group which may contain a substituent, R2 is an alkylene group and R3 is a group which does not hinder the coordination of an imidazolyl group to M.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: October 24, 2006
    Assignee: Japan Science and Technology Agency
    Inventors: Eishun Tsuchida, Teruyuki Komatsu, Yasuko Matsukawa